Logo image of CNTA

CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Fundamental Analysis

NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD

16.23  -0.53 (-3.16%)

After market: 16.23 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CNTA. CNTA was compared to 572 industry peers in the Biotechnology industry. CNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CNTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CNTA has reported negative net income.
CNTA had a negative operating cash flow in the past year.
In the past 5 years CNTA always reported negative net income.
CNTA had a negative operating cash flow in each of the past 5 years.
CNTA Yearly Net Income VS EBIT VS OCF VS FCFCNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

CNTA has a Return On Assets (-39.45%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -54.83%, CNTA is doing good in the industry, outperforming 62.48% of the companies in the same industry.
Industry RankSector Rank
ROA -39.45%
ROE -54.83%
ROIC N/A
ROA(3y)-50.38%
ROA(5y)-53.58%
ROE(3y)-68.59%
ROE(5y)-117.32%
ROIC(3y)N/A
ROIC(5y)N/A
CNTA Yearly ROA, ROE, ROICCNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

CNTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTA Yearly Profit, Operating, Gross MarginsCNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CNTA has been increased compared to 1 year ago.
Compared to 1 year ago, CNTA has a worse debt to assets ratio.
CNTA Yearly Shares OutstandingCNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CNTA Yearly Total Debt VS Total AssetsCNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 8.27 indicates that CNTA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.27, CNTA belongs to the best of the industry, outperforming 86.04% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that CNTA is not too dependend on debt financing.
The Debt to Equity ratio of CNTA (0.27) is worse than 69.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 8.27
ROIC/WACCN/A
WACC9.43%
CNTA Yearly LT Debt VS Equity VS FCFCNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 13.29 indicates that CNTA has no problem at all paying its short term obligations.
CNTA has a better Current ratio (13.29) than 86.91% of its industry peers.
A Quick Ratio of 13.29 indicates that CNTA has no problem at all paying its short term obligations.
CNTA has a better Quick ratio (13.29) than 86.91% of its industry peers.
Industry RankSector Rank
Current Ratio 13.29
Quick Ratio 13.29
CNTA Yearly Current Assets VS Current LiabilitesCNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.71% over the past year.
EPS 1Y (TTM)6.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CNTA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.06%
EPS Next 2Y-0.79%
EPS Next 3Y-2.36%
EPS Next 5Y0.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTA Yearly Revenue VS EstimatesCNTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CNTA Yearly EPS VS EstimatesCNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTA Price Earnings VS Forward Price EarningsCNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTA Per share dataCNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as CNTA's earnings are expected to decrease with -2.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.79%
EPS Next 3Y-2.36%

More info and screens

0

5. Dividend

5.1 Amount

CNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (3/7/2025, 8:15:39 PM)

After market: 16.23 0 (0%)

16.23

-0.53 (-3.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners84.89%
Inst Owner Change16.8%
Ins Owners1.22%
Ins Owner Change-5.51%
Market Cap2.14B
Analysts86.67
Price Target28.41 (75.05%)
Short Float %3.64%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.23%
Min EPS beat(2)-1.54%
Max EPS beat(2)12%
EPS beat(4)3
Avg EPS beat(4)14.25%
Min EPS beat(4)-1.54%
Max EPS beat(4)23.96%
EPS beat(8)6
Avg EPS beat(8)11.09%
EPS beat(12)8
Avg EPS beat(12)7.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.94%
PT rev (3m)-2.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 312.25
P/FCF N/A
P/OCF N/A
P/B 7.46
P/tB 7.46
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.05
BVpS2.18
TBVpS2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.45%
ROE -54.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.38%
ROA(5y)-53.58%
ROE(3y)-68.59%
ROE(5y)-117.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.22%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.29
Quick Ratio 13.29
Altman-Z 8.27
F-Score5
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)510.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
EPS Next Y1.06%
EPS Next 2Y-0.79%
EPS Next 3Y-2.36%
EPS Next 5Y0.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.94%
EBIT Next 3Y-16.5%
EBIT Next 5YN/A
FCF growth 1Y26.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.29%
OCF growth 3YN/A
OCF growth 5YN/A